Compare NUS & RNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NUS | RNA |
|---|---|---|
| Founded | 1984 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Pharmaceuticals | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 222.9M | 222.5M |
| IPO Year | 1996 | 2025 |
| Metric | NUS | RNA |
|---|---|---|
| Price | $4.65 | $8.37 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 20 |
| Target Price | N/A | ★ $69.26 |
| AVG Volume (30 Days) | ★ 429.5K | 347.8K |
| Earning Date | 05-07-2026 | 01-01-0001 |
| Dividend Yield | ★ 3.36% | N/A |
| EPS Growth | ★ 207.80 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $3,176,718,000.00 | N/A |
| Revenue This Year | N/A | $88.12 |
| Revenue Next Year | $7.14 | $18.11 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 48.98 | N/A |
| 52 Week Low | $4.49 | $8.66 |
| 52 Week High | $12.59 | $73.06 |
| Indicator | NUS | RNA |
|---|---|---|
| Relative Strength Index (RSI) | 50.16 | 30.69 |
| Support Level | $4.52 | N/A |
| Resistance Level | $4.96 | $14.39 |
| Average True Range (ATR) | 0.16 | 0.73 |
| MACD | 0.02 | -0.27 |
| Stochastic Oscillator | 62.22 | 10.85 |
Nu Skin Enterprises Inc develops and distributes a comprehensive line of beauty and wellness solutions in various countries. The company operates in two primary product categories: beauty and wellness products. Additionally, the company also operates through its subsidiary, Rhyz. It reports revenue from nine segments, consisting of its seven geographic Nu Skin segments: Americas, Southeast Asia/Pacific, Mainland China, Japan, Europe & Africa, South Korea, and Hong Kong/Taiwan and two Rhyz segments: manufacturing, which includes manufacturing and packaging subsidiaries it has acquired; and Rhyz Other, which includes other investments by its Rhyz strategic investment arm. The majority of the company's revenue is generated from the Wellness product category from the Americas segment.
Atrium Therapeutics Inc is a biopharmaceutical firm focused on developing RNA-based therapeutics for cardiac conditions, including cardiomyopathies. Its platform technology is designed to enable targeted delivery of RNA therapeutics to heart tissue by combining ligand-based targeting approaches with oligonucleotide-based therapies. The company's development pipeline includes programs targeting genetically associated forms of cardiomyopathy, specifically involving the PRKAG2 and PLN genes.